...endpoint Kura Oncology Inc. (NASDAQ:KURA) said four patients with relapsed or refractory urothelial cancer receiving tipifarnib...
...peptide-1 receptor; JAK - Janus kinase Sandi Wong and Hongjiang Li, Staff Writers Aerucin (AR-105) CTP-543 PB-718 selatogrel (ACT-246475) tipifarnib (zarnestra, R115777) Aridis...

...at $17. The fund-raising comes days after newly updated data showed that Kura's lead candidate, tipifarnib...

...the offering after hours. The company gained $0.25 to $17.30 June 28. Kura’s lead candidate, tipifarnib...
...or metastatic HRAS-mutant SCCHN, which it believes could be registrational based on discussions with regulators. Tipifarnib...
...Kura Oncology Inc. (NASDAQ:KURA), San Diego, Calif. Zafgen Inc. (NASDAQ:ZFGN), Boston, Mass. Jaime De Leon tipifarnib (zarnestra, R115777) ZGN-1061 Kura...

...proposed the offering after hours. The company gained $0.25 to $17.30 Thursday. Kura’s lead candidate, tipifarnib...
...or metastatic HRAS-mutant SCCHN, which it believes could be registrational based on discussions with regulators. Tipifarnib...
...early next year. ZGN-1061 is a second-generation methionine aminopeptidase 2 (MetAP2) inhibitor. Jaime De Leon tipifarnib (zarnestra, R115777) ZGN-1061 Kura...

...human colorectal cancer cell line treated with alphavirus M1, co-treatment with the farnesyl transferase inhibitor tipifarnib...
...tipifarnib had no effect on viral replication. In human colorectal and pancreatic cancer cell lines, tipifarnib...
...additional models of colorectal and pancreatic cancers. Johnson & Johnson and Kura Oncology Inc. have tipifarnib...

...cell carcinoma of the head and neck (SCCHN) in a Phase II trial showing that tipifarnib...
...Phase III trial of tipifarnib to treat HRAS-mutant SCCHN this year. In September, Kura said tipifarnib...
...protocol required at least four confirmed partial responses out of 18 patients. At the time, tipifarnib...

...patients with wild-type RAS chronic myelomonocytic leukemia (CMML) in a Phase II trial showing that tipifarnib...
...NYSE:JNJ) (see BioCentury, March 16, 2015 ). Kura Oncology Inc. (NASDAQ:KURA), La Jolla, Calif. Elizabeth S. Eaton tipifarnib Kura...

...seven evaluable patients with mutant RAS CMML, tipifarnib led to 6 cases of stable disease. Tipifarnib...
...This year, the company plans to begin a registration-enabling study of tipifarnib for HRAS-mutant SCCHN. Tipifarnib...
...Inc. (NASDAQ:KURA), La Jolla, Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Tipifarnib (formerly Zarnestra...

...that back and more not quite a month later when it reported that lead asset tipifarnib...

...Kura Oncology Inc. (NASDAQ:KURA) said tipifarnib met the primary endpoint in a Phase II trial to...
...available options to advance the development of tipifarnib for HRAS-mutant SCCHN "as quickly as possible.” Tipifarnib...
...Inc. (NASDAQ:KURA), La Jolla, Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Tipifarnib (formerly Zarnestra...